Literature DB >> 21204705

Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.

Peter Bell1, Guangping Gao, Mark E Haskins, Lili Wang, Meg Sleeper, Huan Wang, Roberto Calcedo, Luk H Vandenberghe, Shu-Jen Chen, Chick Weisse, Elanor Withnall, James M Wilson.   

Abstract

This study evaluated six adeno-associated viral (AAV) vectors expressing green fluorescent protein (GFP) from the liver-specific thyroid hormone-binding globulin (TBG) promoter made with novel capsids in canine liver-directed gene transfer. Studies in 1.5-month-old dogs, which were administered vector through a peripheral vein, showed that AAV8 capsid vectors had the most favorable performance profiles. Interestingly, the absolute levels of hepatocyte transduction achieved with AAV8 were lower in dogs compared with what had been achieved in mice and nonhuman primates. Additional studies were performed with AAV8 delivered into the hepatic artery in adult dogs, with higher doses of vector used to assess potential dose-limiting toxicities. These studies showed good transduction on day 7 in one dog that apparently was lost by day 28 in another dog through the generation of GFP-specific T cells. Each adult dog was carefully monitored for any hemodynamic changes associated with vector infusion. Both animals demonstrated mild to moderate hypotension and bradycardia, which appeared to be anesthesia-related, making it difficult to evaluate contributions of the vector.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21204705      PMCID: PMC3159528          DOI: 10.1089/hum.2010.194

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  53 in total

1.  Target-controlled infusion of propofol in dogs--evaluation of four targets for induction of anaesthesia.

Authors:  G C Musk; D S J Pang; T Beths; D A Flaherty
Journal:  Vet Rec       Date:  2005-12-10       Impact factor: 2.695

2.  Modified infusion procedures affect recombinant adeno-associated virus vector type 2 transduction in the liver.

Authors:  Kazuo Ohashi; Hiroyuki Nakai; Linda B Couto; Mark A Kay
Journal:  Hum Gene Ther       Date:  2005-03       Impact factor: 5.695

3.  No evidence for tumorigenesis of AAV vectors in a large-scale study in mice.

Authors:  Peter Bell; Lili Wang; Corinna Lebherz; Douglas B Flieder; Mark S Bove; Di Wu; Guang Ping Gao; James M Wilson; Nelson A Wivel
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

4.  Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates.

Authors:  Guangping Gao; You Lu; Roberto Calcedo; Rebecca L Grant; Peter Bell; Lili Wang; Joanita Figueredo; Martin Lock; James M Wilson
Journal:  Mol Ther       Date:  2005-10-10       Impact factor: 11.454

5.  Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models.

Authors:  Andrew M Davidoff; John T Gray; Catherine Y C Ng; Youbin Zhang; Junfang Zhou; Yunyu Spence; Yusura Bakar; Amit C Nathwani
Journal:  Mol Ther       Date:  2005-06       Impact factor: 11.454

Review 6.  Large animal models and gene therapy.

Authors:  Margret Casal; Mark Haskins
Journal:  Eur J Hum Genet       Date:  2006-03       Impact factor: 4.246

7.  Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.

Authors:  Lili Wang; Roberto Calcedo; Timothy C Nichols; Dwight A Bellinger; Aaron Dillow; Inder M Verma; James M Wilson
Journal:  Blood       Date:  2005-01-06       Impact factor: 22.113

8.  Mechanisms whereby propofol mediates peripheral vasodilation in humans. Sympathoinhibition or direct vascular relaxation?

Authors:  B J Robinson; T J Ebert; T J O'Brien; M D Colinco; M Muzi
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

Review 9.  Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?

Authors:  K High
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

10.  Effect of propofol on heart rate, arterial pressure and digital plethysmograph variability.

Authors:  B J Robinson; H C Buyck; D C Galletly
Journal:  Br J Anaesth       Date:  1994-08       Impact factor: 9.166

View more
  25 in total

Review 1.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

2.  Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Authors:  Brittney L Gurda; Christina Raupp; Ruth Popa-Wagner; Matthias Naumer; Norman H Olson; Robert Ng; Robert McKenna; Timothy S Baker; Jürgen A Kleinschmidt; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta).

Authors:  Lili Wang; Peter Bell; Jianping Lin; Roberto Calcedo; Alice F Tarantal; James M Wilson
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

Review 4.  Engineering adeno-associated viruses for clinical gene therapy.

Authors:  Melissa A Kotterman; David V Schaffer
Journal:  Nat Rev Genet       Date:  2014-05-20       Impact factor: 53.242

5.  Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

Authors:  R F Boyd; S L Boye; T J Conlon; K E Erger; D G Sledge; I M Langohr; W W Hauswirth; A M Komáromy; S E Boye; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2016-04-07       Impact factor: 5.250

Review 6.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

7.  Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.

Authors:  Christian Hinderer; Peter Bell; Jean-Pierre Louboutin; Yanqing Zhu; Hongwei Yu; Gloria Lin; Ruth Choa; Brittney L Gurda; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Alice F Tarantal; Margret L Casal; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2015-05-29       Impact factor: 11.454

Review 8.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

9.  CpG-depleted adeno-associated virus vectors evade immune detection.

Authors:  Susan M Faust; Peter Bell; Benjamin J Cutler; Scott N Ashley; Yanqing Zhu; Joseph E Rabinowitz; James M Wilson
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

10.  Generation and characterization of anti-Adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies.

Authors:  Yu-Shan Tseng; Kim Van Vliet; Lavanya Rao; Robert McKenna; Barry J Byrne; Aravind Asokan; Mavis Agbandje-McKenna
Journal:  J Virol Methods       Date:  2016-07-14       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.